Introduction
Thyroid hormone 3,5,3'-triiodothyronine (T3) is an important regulator of key cellular processes, including proliferation, apoptosis, and metabolism. The proteins involved in T3 signalling pathway include thyroid hormone receptors (THR) that regulate expression of target genes in a T3-dependent manner. Previous studies revealed that T3-THR actions are disturbed in cancers, including renal tumours [1] [2] [3] [4] , and actively contribute to the process of cancerogenesis. The transcriptional activity of THRs is regulated by co-regulatory proteins, including TRIP11.
TRIP11 is a multifunctional protein involved in functioning of Golgi apparatus and regulation of gene expression. Coincidently with its different functions, TRIP11 can localise either to Golgi apparatus, acting as a golgin [5] , or the nucleus, acting as coactivator of transcription. TRIP11 (also named TRIP230 and GMAP-210) was initially discovered as a protein interacting with retinoblastoma protein (Rb) and THR [6] . In the presence of T3, TRIP11 binds THRs and enhances THRdependent transcription. Furthermore, TRIP11 acts also as a coactivator of hypoxia-inducible factor (HIF). By binding to ARNT (HIF-1β), a dimerisation partner of HIF-1α, TRIP11 contributes to the activation of HIF-1α-regulated genes [7] . The coactivator function of TRIP11 is inhibited by retinoblastoma protein that interacts with TRIPI11 and interferes with its binding to THRB and ARNT [8] .
The transcription-related functions of TRIP11 indicate that it acts on the crossroads of two important signalling pathways, induced by hypoxia and thyroid hormones. Remarkably, both these pathways are involved in carcinogenic process. Hypoxia and activation of HIFs are a hallmark of solid tumours, resulting in stimulation of multiple genes that promote cancer progression [9] . Likewise, T3 and its receptors also influence multiple genes involved in cancer development and progression [1, 10, 11] . Remarkably, both these pathways share common gene targets, such as VEGF (vascular endothelial growth factor) or GLUT1 (glucose transporter 1) [12] [13] [14] [15] .
The knowledge of mechanisms that regulate functioning of TRIP11 is thus important for understanding the tumour-related alterations in signalling pathways induced by hypoxia and T3. The activity of TRIP11 in the cell highly depends on its subcellular localisation. Remarkably, it was shown that T3 regulates nuclear localisation of TRIP11 by inducing its phosphorylation [16] . The exact mechanism of this regulation is, however, unknown.
Regarding the significance of TRIP11 in the regulation of two signalling pathways important for cancer initiation and progression, in this work we aimed to analyse the mechanism of T3-induced cellular localisation of TRIP11. Furthermore, taking into consideration that both TRIP11-related pathways (induced by hypoxia and T3) are disturbed in renal cancer, we also explored the network of correlations between the genes involved in hypoxia and T3 signalling as well as the significance of TRIP11 and T3 signalling pathway in the progression of this tumour.
Material and Methods

Cell culture and immunocytochemistry
Caki-2 cells (ATCC -HTB-47) were cultured according to manufacturer protocol. 0.4 × 10 5 cells were seeded on Φ12-mm ethanol sterilised cover slides (Carl Roth GmbH Karlsruhe, Germany) placed in 24-well plates, and cultured in medium supplemented with charcoalstripped FBS (Sigma-Aldrich, St. Louis, MO, USA). After 24-h incubation the medium was renewed and cells were treated for one hour with 100 nM wortmannin (Sigma-Aldrich, St. Louis, MO, USA) or vehicle. Medium was renewed and T3 (Sigma Aldrich), T3-agarose (MPBiomedicals, Eschwege, Germany), or vehicle was added. Following one hour of treatment the cells were fixed with 4% paraformaldehyde, rinsed with PBS, incubated (3 × 5 minutes) with detergents [0.5% saponin and 0.5% Triton X-100 (Sigma Aldrich)], and incubated for one hour in blocking buffer [10% horse serum and 0.3% Triton X-100 in PBS (Sigma Aldrich)]. Then cells were incubated overnight at 4°C with anti-TRIP11 antibody (BD Biosciences, Franklin Lakes, NJ, USA) diluted 1:50 in PBS with 2% horse serum, and 0.3% Triton X-100. The slides were washed (3 × 5 minutes) with washing buffer (2% horse serum and 0.3% Triton X-100 in PBS), incubated for one hour with blocking buffer, and incubated for 20 minutes with secondary anti-mouse antibody conjugated with fluorophore Cy2 (Abcam, Cambridge, UK). Following additional washes (3 × 5 minutes) with washing buffer, the cells were incubated for five minutes with DAPI (100 ng/ml) (Sigma Aldrich) in PBS, then washed again and fixed on slides with Fluoromount (Sigma Aldrich), dried, and observed with an Axio Observer D1 (Carl Zeiss, Berlin, Germany) equipped with a 100X oil-immersion objective. 
RNA isolation and cDNA synthesis
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Reverse transcriptions were performed on 100 ng of RNA using Revert Aid H Minus First Strand cDNA Synthesis Kit and random hexamers (Thermo Fisher Scientific, Rockford, IL, USA) according to the manufacturer's instructions.
Real-time quantitative PCR
Real-time quantitative PCR (qPCR) was performed using Taqman probes (Thermo Fisher Scientific) designed to detect 18SRNA (Hs03928985_g1), ARNT (Hs00231048_m1), FURIN (Hs00965485_g1), HPRT (HS-02800695), SLC2A1 (GLUT1) (Hs00892681_m1), THRA (Hs00268470_m1), THRB (Hs00230861_m1), TRIP11 (Hs00188542_m1), VEGFA (Hs00900055_m1), and TaqManUniversal Master MiX II (Thermo Fisher Scientific), according to the manufacturer's instructions.
Statistical analysis
Statistical analysis was performed with GraphPad Prism 5.00 for Windows (GraphPad Software, San Diego, CA, USA) using the Shapiro-Wilk normality test, Wilcoxon matched pair signed rank test, paired t-test, 1-way ANOVA with Bonferroni multiple comparisons post-test, and Kruskal-Wallis test with Dunn's Multiple Comparison Test. P < 0.05 was considered statistically significant. Survival rate analysis was performed as described previously [17] , using the SurvExpress platform [18] and data retrieved from TCGA (https://tcga-data. nci.nih.gov, [19] ).
Results
T3 induces nuclear TRIP11 localisation via PI3K--dependent mechanism
In agreement with the previous study [16] treatment of Caki-2 cells with T3 resulted in translocation of TRIP11 from Golgi complex to the nucleus (Fig. 1) . We hypothesised that this T3 effect could be mediated by PI3K, previously shown to be activated by thyroid hormone [20, 21] . To test this hypothesis, we pre-treated the cells with specific PI3K inhibitor, wortmannin. This treatment completely abolished the T3 effect on TRIP11 localisation (Fig. 1B) .
T3 effect on TRIP11 is not mediated by membrane-bound receptors
T3 activates PI3K pathway by two mechanisms: either by THRB-mediated activation of p85α PI3K subunit in the cytoplasm [21] or by the mechanisms involving the membrane receptor, integrin αvβ3 [23] . To test the latter possibility, Caki-2 cells were cultured in the presence of T3-agarose, which precludes intracellular T3 actions. None of the five tested T3-agarose concentrations resulted in translocation of TRIP11 to the nucleus (Fig. 2 ).
This indicated that the effect of T3 on TRIP11 does not involve membrane receptors.
Expressions of TRIP11 and ARNT are disturbed in renal cancer
TRIP11 is a coactivator of signalling pathways induced by T3 and hypoxia [6] [7] [8] . Therefore, we analysed the expression TRIP11, as well as ARNT and genes involved in T3-signalling pathway in renal tumours. We also addressed the expression of FURIN, VEGFA, and GLUT1, known to be commonly regulated by HIFs and thyroid hormone pathway [12, 13, 15, 24, 25] .
The expression of TRIP11 mRNA was statistically significantly (p = 1.5 × 10 -3 ) decreased -2.01 fold in RCC tumour samples when compared with matchedpaired controls (Fig. 3 ). In agreement with previous studies [2] [3] [4] , the expressions of THRA and THRB were also significantly reduced in renal tumours (-1.27 fold p = 2.0 × 10 , respectively). The expression ARNT trended to increase (1.22 fold) in RCC tumours; however, this change was not statistically significant (Fig. 3) .
Next, we analysed the expression of genes that are known targets of both, hypoxia-and T3-induced pathways. The expression of VEGFA (4.56 fold) and GLUT1 (3.96 fold) was statistically significantly (p = 5.0 × 10 -4 and p < 1.0 × 10 -4
, respectively) induced in RCC tumours when compared with control samples (Fig. 3 ). There was a trend for decreased expression of FURIN (-1.95 fold); however, it did not reach statistical significance (p = 8.1 × 10 -2 ) (Fig. 3) . Remarkably, similar changes in expression of investigated genes were also confirmed on independent cohort of 534 RCC tumours and 72 non-tumorous controls (data obtained from TCGA, [19] ) ( Supplementary Fig. 1 ).
The expressions of genes involved in T3 signalling and hypoxia are correlated in RCC tumours
To see the potential changes in the network of interactions between T3 signalling and hypoxia, we analysed correlations between the expression levels of studied genes. In agreement with known cooperation of the analysed genes, we found that in control samples the expression of TRIP11 was highly correlated (r Spearman > 0.75, p < 3.0 × 10 -8 ) with expressions of THRA, THRB, ARNT, FURIN, VEGFA, and GLUT1. Strikingly, in tumour samples TRIP11 did not correlate with VEGFA and GLUT1 (Fig. 4 and Supplementary Fig. 2) . Similarly, the correlations between THRs and ARNT, VEGFA, and GLUT1 were much weaker or even lost in tumour samples comparing to controls (Fig. 4) . These results possibly suggested that in RCC tumours the expression of VEGFA and GLUT1 might not be further controlled by T3 signalling.
Disturbed expression of TRIP11 and ARNT correlates with RCC tumour grade
Next, to check the association of TRIP11 and ARNT with tumour pathology, we analysed their expression in different RCC tumour grades. To ensure the appropriate number of samples for statistical analysis, we took advantage of the publically available data of The Cancer Genome Atlas network (TCGA) [19] . The expressions of TRIP11 and ARNT statistically significantly decreased with increase of tumour grade (Fig. 5 ). In agreement with previous studies, expressions of THRA and THRB were also lowered in higher tumour grades (Fig. 5) .
Disturbed expression of genes involved in T3 signalling correlates with poor survival of RCC patients
Finally, we tested the associations between the expression of T3 signalling genes and survival of RCC patients ( , respectively). When the integrated signature of expression of all three genes was tested, the effect on patient survival was even stronger (HR = 2.6, p = 1.6 × 10 
Rycina 1. Blokowanie indukowanej przez T3 zmiany lokalizacji TRIP11 przez wortmaninę. A. Komórki hodowane bez T3 -TRIP11 jest zlokalizowany w cytoplazmie (prawdopodobnie w aparacie Golgiego); B. Komórki traktowane 100nM T3 -TRIP11 jest zlokalizowany w jądrze komórkowym; C. Komórki preinkubowane z 100nM wortmaniną i hodowane w obecności 100nM T3 -TRIP11 jest zlokalizowany w cytoplazmie (prawdopodobnie w aparacie Golgiego). Zdjęcia komórek linii Caki-2 wykonano z wykorzystaniem mikroskopu Zeiss Axio Observer D1 wyposażonego w obiektyw immersyjny o powiększeniu 100x, barwione DAPI (pierwsza kolumna), znakowane przeciwciałem anti-TRIP11 (druga kolumna). Scalone zdjęcia są pokazane w trzeciej kolumnie
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Figure 2. Triiodothyronine-agarose treatment has no influence on TRIP11 localisation. A. Cells treated with low T3-agarose concentration (100 nM) -TRIP11 localises in cytoplasm (probably in Golgi apparatus); B. Cells treated with medium T3-agarose concentration (200 nM) -TRIP11 localises in cytoplasm (probably in Golgi apparatus); C. Cells treated with high T3-agarose concentration (600 nM) -TRIP11 localises in cytoplasm (probably in Golgi apparatus). Similar results were obtained for 30 nM, 200 nM and 1800 nM T3-agarose concentrations. Images of Caki-2 cells were taken using a Zeiss Axio Observer D1 microscope equipped with 100X oilimmersion objective, stained with DAPI (first column), anti-TRIP11 antibody (second column), and merged (third column)
Rycina 2. Brak wpływu T3 sprzężonego z agarozą na lokalizację TRIP11. A. Komórki traktowane niskim stężeniem T3-agarozy (100nM) -TRIP11 jest zlokalizowany w cytoplazmie (prawdopodobnie w aparacie Golgiego); B. Komórki traktowane średnim stężeniem T3-agarozy (200nM) -TRIP11 jest zlokalizowany w cytoplazmie (prawdopodobnie w aparacie Golgiego); C. Komórki traktowane wysokim stężeniem T3-agarozy (200nM) -TRIP11 jest zlokalizowany w cytoplazmie (prawdopodobnie w aparacie Golgiego). Identyczne wyniki osiągnięto dla T3-agarozy w stężeniach 30nM, 200nM i 1800 nM. Zdjęcia komórek linii Caki-2 wykonano z wykorzystaniem mikroskopu Zeiss Axio Observer D1 wyposażonego w obiektyw immersyjny o powiększeniu 100x, barwione DAPI (pierwsza kolumna), znakowane przeciwciałem anti-TRIP11 (druga kolumna). Scalone zdjęcia są pokazane w trzeciej kolumnie
Discussion
In this study, we showed for the first time that T3 regulates subcellular localisation of TRIP11 by a mechanism involving PI3K kinase. We also revealed that renal tumours are characterised by changes in coregulatory network of T3 and hypoxia signalling pathway and showed that altered expression of genes involved in thyroid hormone signalling correlates with poor survival of renal cancer patients.
FURIN, GLUT1, and VEGFA are genes actively contributing to carcinogenic process. FURIN is a proprotein convertase that activates precursor proteins by amino acid sequence-specific cleavage. The expression of FURIN is often disturbed in cancers and contributes to activation of cancer-promoting proteins such as TGF-β1 [24, 25] . GLUT1 is a glucose transporter commonly upregulated in cancers, which facilitates enhanced glucose uptake and the pro-proliferative metabolic switch in tumour cells [26] . VEGFA is an important growth factor enabling activation of angiogenesis in solid tumours [27] [28] [29] [30] [31] [32] . Remarkably, all of these three genes are commonly regulated by thyroid hormone signalling and hypoxia [12-14, 23, 24] . In agreement with this, in nontumorous kidney control samples we observed strong correlations between the expression of genes involved in hypoxia and T3 signalling. In contrast, these correlations were weakened or even lost in RCC tumours (Fig. 4) . This might suggest that in tumour cells the control of some genes by T3 signalling is lost. Indeed, RCC tumours are characterised by decreased expression of THRs [2] [3] [4] . Furthermore, it was shown that THRB may counteract PI3K activation in cancer cells, leading to attenuation of VEGF activation [13] . Thus, the loss of THRB in RCC tumours might further contribute to induction of VEGF expression. Moreover, T3 concentrations in RCC tumours are also significantly suppressed [3] . This could imply that T3-dependent nuclear targeting of TRIP11 might be impaired in RCC tumours and in turn disturb the co-activator functions of TRIP11. To verify this hypothesis, the possible changes in subcellular localisation of TRIP11 in RCC tumours should be analysed. Depletion of TRIP11 from mouse embryos leads to fragmentation of Golgi apparatus in kidney cells, thus interfering with secretory trafficking [33] . It was also suggested that TRIP11 may play a specific role in secretion of extracellular matrix proteins [34] . Remarkably, disturbances in expression and secretion of ECM proteins contribute to the progression of renal and other cancers [17, 35, 36] . Thus, disturbed expression of TRIP11 might also contribute to alterations in ECM of renal tumours. This possibility should be also experimentally evaluated. When confirmed, this could at least partially explain the mechanism by which decreased TRIP11 expression may contribute to the lower survival of RCC patients.
Finally, the possible protective role of T3 signalling in cancer is in agreement with the well-known tumour suppressive roles of THRB [13, 37] . The results of our study fit this model well because decreased expression of genes involved in T3 signalling correlated with poor survival of RCC patients (Fig. 6) .
The significance of our results might expand beyond the molecular basis of carcinogenesis. TRIP11 is indispensable for proper development of bone, and its loss in mice leads to lethal skeletal dysplasia [33] . Furthermore, patients with achondrogenesis type 1A, a neonatal, lethal form of skeletal dysplasia, bear inactivating mutations in the TRIP11 gene [33] . It is known that thyroid hormones are indispensable for proper development and that mutation in THRs or changes in intracellular T3 levels lead to disturbances in bone formation [38] . These effects are explained mainly by loss of T3-dependent effects on gene expression. However, it may be hypothesised that spatio-temporal intracellular changes in T3 may also contribute to the process of bone formation by affecting TRIP11 localisation. This hypothesis should be verified by future studies.
Conclusions
To sum up, this study revealed the PI3K-involving mechanism by which T3 regulates intranuclear trafficking of TRIP11. We also demonstrated changes in the network of genes involved in hypoxia and thyroid hormone signalling, possibly indicating the loss of T3 control on expression of targets involved in the regulation of tumour progression. The study shows for the first time that disturbed expression of T3 signalling pathway genes correlates with progression of RCC. The specific mechanisms by which altered expression of genes involved in T3 signalling contribute to poor survival of RCC patients require further investigation. 
